Abdulfatah Elshaar, MD
Internal Medicine · Norwood, MANPI 1821045550
Payments from drug & device makers
Across 529 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$894
- GSK$803
- AstraZeneca$800
- Lilly USA, LLC$614
- Novartis$577
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,358100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $1,893 |
| Pfizer | 52 | $894 |
| GSK | 45 | $803 |
| AstraZeneca | 44 | $800 |
| Lilly USA, LLC | 32 | $614 |
| Novartis | 32 | $577 |
| Amgen | 26 | $487 |
| Boehringer Ingelheim | 25 | $469 |
| Novo Nordisk | 25 | $468 |
| E.r. Squibb & Sons, L.L.C. | 16 | $318 |
| Amarin Pharma, Inc. | 16 | $275 |
| Johnson & Johnson | 12 | $181 |
| Esperion Therapeutics, Inc. | 9 | $160 |
| Nestle Healthcare Nutrition Inc. | 8 | $154 |
| Sunovion Pharmaceuticals Inc. | 6 | $134 |
| Abbott | 2 | $134 |
| Exact Sciences | 6 | $123 |
| Astellas Pharma US Inc | 6 | $123 |
| Bayer | 6 | $119 |
| Sumitomo Pharma America, Inc. | 5 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Shield Therapeutics Inc | 3 | $51 |
| Eisai Inc. | 3 | $49 |
| Verona Pharma, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Biogen | 2 | $39 |
| Lucid Diagnostics Inc. | 2 | $32 |
| Acerus Pharmaceuticals Corporation | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Circassia Inc. | 2 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Insmed, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,370 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $175,404 |
| TrulicityDulaglutide | 96 | $100,152 |
| OzempicSemaglutide | 96 | $98,400 |
| JardianceEmpagliflozin | 96 | $94,915 |
| FarxigaDapagliflozin Propanediol | 83 | $79,417 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $61,749 |
| TradjentaLinagliptin | 28 | $37,208 |
| XareltoRivaroxaban | 20 | $32,287 |
| JanuviaSitagliptin Phosphate | 26 | $26,596 |
| MounjaroTirzepatide | 23 | $25,015 |
| CreonLipase/Protease/Amylase | 11 | $19,055 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $17,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,512 |
| Atorvastatin Calcium | 743 | $11,107 |
| Metoprolol Succinate | 384 | $8,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $894 | $175,404138 claims |
| Boehringer IngelheimJardiance, Tradjenta | $469 | $132,124124 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $614 | $125,167119 claims |
| Novo NordiskOzempic | $468 | $98,40096 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $800 | $94,072109 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $803 | $84,20288 claims |
| Johnson & JohnsonXarelto | $181 | $32,28720 claims |
| AbbVieCreon | $1,893 | $19,05511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Norwood
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.